Quantcast

Latest Cholangiocarcinoma Stories

2014-08-11 08:28:38

TORONTO, ON and CHICAGO, IL, Aug. 11, 2014 /PRNewswire/ - Concordia Healthcare Corp. ("Concordia") (TSX: CXR) (OTCQX: CHEHF), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, announced today that its subsidiary Pinnacle Biologics, Inc., a biopharmaceutical research and development company specializing in rare diseases, enrolled the first patients in a randomized Phase 2 trial to evaluate...

2014-08-05 08:33:22

Thomas Jefferson University Hospital is first site opened, more sites scheduled in August TORONTO AND CHICAGO, Aug. 5, 2014 /PRNewswire/ - Concordia Healthcare Corp. ("Concordia") (TSX: CXR) (OTCQX: CHEHF), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, and its subsidiary Pinnacle Biologics, Inc., a biopharmaceutical research and development company specializing in rare diseases, today...

2014-07-09 11:33:39

The Mount Sinai Hospital / Mount Sinai School of Medicine Two genetic mutations in liver cells may drive tumor formation in intrahepatic cholangiocarcinoma (iCCA), the second most common form of liver cancer, according to a research published in the July issue of the journal Nature. A team led by the Icahn School of Medicine at Mount Sinai and Harvard Medical School has discovered a link between the presence of two mutant proteins IDH1 and IDH2 and cancer. Past studies have found IDH...

2014-06-17 04:21:42

Proof-of-Concept Trial Targets DNA Repair in Bile Duct Cancers SAN DIEGO and NEW TAIPEI CITY, Taiwan, June 17, 2014 /PRNewswire-iReach/ -- Senhwa Biosciences, Inc. announced today that the Company has initiated a randomized Phase 1b/2 Trial of CX-4945 in combination with gemcitabine and cisplatin for the frontline treatment of patients with bile duct cancers (cholangiocarcinoma). This Proof-of-Concept trial will study the use of CX-4945, a small molecule CK2 inhibitor, to suppress...

2014-04-09 23:29:35

Cancers of the liver are increasing in incidence faster than any other cancer in the U.S. and other western countries, and are a leading cause of cancer death worldwide. CanLiv - The Hepatobiliary Cancers Foundation will bring together researchers, cancer doctors, patient advocates, and industry partners to collaboratively develop better treatment for liver cancer patients at its 4th Annual Research Symposium, May 9, 2014 at ASCO Conference Center in Alexandria, VA. Alexandria, VA...

2014-03-26 08:28:35

Supplemental approval will expand PDT with Photofrin® treatments in specific lung and esophageal cancers TORONTO AND BANNOCKBURN, IL, March 26, 2014 /PRNewswire/ - Concordia Healthcare Corp. (Concordia or the Company) (TSX:CXR) (OTCQX: CHEHF) announced today that its subsidiary Pinnacle Biologics, Inc. (Pinnacle), a biopharmaceutical research and development company specializing in rare diseases, was granted U.S. Food and Drug Administration (FDA) premarket supplemental...

2014-01-13 08:27:08

Agreement represents continued movement forward in the development of a potential new treatment for rare cancers TORONTO and BANNOCKBURN, Ill., Jan. 13, 2014 /PRNewswire/ -- Concordia Healthcare Corp. ("Concordia" TSX:CXR) announced today that its subsidiary Pinnacle Biologics, Inc. ("Pinnacle"), a biopharmaceutical research and development company specializing in rare diseases, has reached an agreement with the U.S. Food and Drug Administration (the "FDA") under a special protocol...

2013-11-04 10:40:59

A team of scientists from the National Cancer Centre Singapore, Duke-NUS Graduate Medical School Singapore, Fundeni Clinical Institute (Romania) and Koen Kaen University (Thailand), have made a seminal breakthrough in understanding the molecular basis of bile duct cancer or cholangiocarcinoma, a rare but highly lethal form of liver cancer. The team, led by Professors Teh Bin Tean, Patrick Tan, Steve Rozen, Irinel Popescu and Vajaraphongsa Bhudhisawasdi, used advanced DNA sequencing...

2013-10-09 12:49:29

Among patients with pancreatic cancer who had surgery for removal of the cancer, treatment with the drug gemcitabine for 6 months resulted in increased overall survival as well as disease-free survival, compared with observation alone, according to a study in the October 9 issue of JAMA. "Pancreatic cancer is a disease with a poor prognosis, mainly because of the inability to detect the tumor at an early stage, its high potential for early dissemination, and its relatively poor sensitivity...


Latest Cholangiocarcinoma Reference Libraries

Chinese Liver Fluke, Clonorchis sinensis
2014-01-12 00:00:00

The Chinese liver fluke (Clonorchis sinensis) is a species of parasitic worm that is classified within the Platyhelminthes phylum. It can be found in Southeast Asia, Taiwan, Japan, and China and is present in nearly 30,000,000 humans today. It is thought to be one of the world’s most pervading parasites. The Chinese liver fluke requires two intermediate, or secondary, hosts and one definitive, or main, host to successfully complete its lifecycle. The first intermediate host is typically...

More Articles (1 articles) »
Word of the Day
monteith
  • A large punch-bowl of the eighteenth century, usually of silver and with a movable rim, and decorated with flutings and a scalloped edge. It was also used for cooling and carrying wine-glasses.
  • A kind of cotton handkerchief having white spots on a colored ground, the spots being produced by a chemical which discharges the color.
This word is possibly named after Monteith (Monteigh), 'an eccentric 17th-century Scotsman who wore a cloak scalloped at the hem.'
Related